Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease

Next Previous
X
Search
Trial Profile

A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 01 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atabecestat (Primary) ; E 2814 (Primary) ; Florquinitau F18 (Primary) ; Gantenerumab (Primary) ; Lecanemab (Primary) ; Solanezumab (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Acronyms DIAN-TU; DIAN-TU-001; Tau NexGen Study

    • Most Recent Events

    • 03 Jul 2024 Planned End Date changed from 1 Oct 2027 to 1 Jul 2028.
    • 03 Jul 2024 Planned primary completion date changed from 1 Oct 2027 to 1 Apr 2028.
    • 01 Jul 2023 Results (n=66) assessing Longitudinal head-to-head comparison of 11C-PiB and 18F-florbetapir PET in dominantly inherited Alzheimer's disease published in the European Journal of Nuclear Medicine and Molecular Imaging

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top